Related Experiment Video
Updated: Jun 2, 2026
06:58
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Preventing Alzheimer's disease and cognitive decline.
John W Williams1, B L Plassman, J Burke
1Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, MD 20850, USA.
Evidence Report/Technology Assessment
|April 20, 2011
Summary
Current research on Alzheimer's disease (AD) risk factors is insufficient for intervention recommendations. More rigorous studies are needed to confirm associations and guide prevention strategies for AD and cognitive decline.
Area of Science:
- Neuroscience
- Gerontology
- Public Health
Background:
- Alzheimer's disease (AD) and cognitive decline are significant public health concerns.
- Identifying reliable risk and protective factors is crucial for developing effective prevention strategies.
- Existing research on various factors requires critical evaluation for its strength and applicability.
Purpose of the Study:
- To evaluate the existing evidence on risk and protective factors for Alzheimer's disease (AD) and cognitive decline.
- To determine if the current research is robust enough to support recommendations for behavioral, lifestyle, or pharmaceutical interventions.
- To inform an upcoming National Institutes of Health (NIH) State-of-the-Science Conference on AD prevention.
Main Methods:
- A comprehensive literature search was conducted using MEDLINE and the Cochrane Database of Systematic Reviews.
- A systematic review and expert evaluation of 25 systematic reviews and 250 primary studies were performed.
- Factors were categorized into nutritional, medical conditions, medications, social/behavioral, environmental, and genetic domains, assessing outcomes related to AD and cognitive decline.
Main Results:
- Few factors demonstrated consistent associations with AD or cognitive decline across studies.
- Increased risk was associated with diabetes, APOE e4 gene, smoking, and depression.
- Decreased risk was linked to cognitive engagement and physical activities, though evidence quality was often low.
Conclusions:
- The current body of research on putative risk and protective factors for AD and cognitive decline is largely inadequate.
- Insufficient evidence prevents confident assessment of associations and precludes making evidence-based recommendations for interventions.
- Further high-quality research, particularly rigorous observational studies, is necessary to inform prevention strategies.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...